

REFERENCES- ECMM/MSGERC ASPERGILLUS WORKING GROUP 10/1/24

1. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;50(8):1101-1111. doi:10.1086/651262
2. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;50(8):1091-1100. doi:10.1086/651263
3. Denning DW. Global incidence and mortality of severe fungal disease. *The Lancet Infectious Diseases*. doi:10.1016/S1473-3099(23)00692-8
4. Hoenigl M, Salmanton-García J, Walsh TJ, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. *Lancet Infect Dis*. Feb 16 2021;doi:10.1016/s1473-3099(20)30784-2
5. Hoenigl M, Seidel D, Sprute R, et al. COVID-19-associated fungal infections. *Nat Microbiol*. Aug 2 2022;doi:10.1038/s41564-022-01172-2
6. Hoenigl M, Sprute R, Egger M, et al. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. *Drugs*. Oct 9 2021;1-27. doi:10.1007/s40265-021-01611-0
7. Hoenigl M, Arastehfar A, Arendrup MC, et al. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease. *Clin Microbiol Rev*. Jun 13 2024;37(2):e0007423. doi:10.1128/cmr.00074-23
8. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. *Clin Infect Dis*. Sep 1 2008;47(5):674-83. doi:10.1086/590566
9. Walsh TJ. Meeting the Therapeutic Challenges of Emergent and Rare Invasive Fungal Diseases Through Novel Clinical Trial Designs. *Open Forum Infect Dis*. Jun 2024;11(6):ofae257. doi:10.1093/ofid/ofae257
10. Maertens J, Slavin M, Hoenigl M, Thompson GR, 3rd, Richardson M, Lass-Flörl C. Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases-a debate. *J Antimicrob Chemother*. Aug 1 2024;79(8):1786-1793. doi:10.1093/jac/dkae158
11. Fernández-Cruz A, Lewis RE, Kontoyiannis DP. How Long Do We Need to Treat an Invasive Mold Disease in Hematology Patients? Factors Influencing Duration of Therapy and Future Questions. *Clin Infect Dis*. Jul 27 2020;71(3):685-692. doi:10.1093/cid/ciz1195
12. Stemler J, de Jonge N, Skoetz N, et al. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. *Lancet Haematol*. May 2022;9(5):e361-e373. doi:10.1016/S2352-3026(22)00073-4
13. Miceli MH, Maertens J, Buvé K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications. *Cancer*. Jul 1 2007;110(1):112-20. doi:10.1002/cncr.22738
14. Koehler P, Cornely OA, Böttiger BW, et al. COVID-19 Associated Pulmonary Aspergillosis. *Mycoses*. Apr 27 2020;doi:10.1111/myc.13096
15. Bassetti M, Giacobbe DR, Agvald-Ohman C, et al. Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM. *Intensive Care Med*. Mar 21 2024;doi:10.1007/s00134-024-07341-7

16. Services/NIH/NCI. DoHaH. *Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0*. November 27, 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
17. Walsh TJ, McCarthy MW. The expanding use of matrix-assisted laser desorption/ionization-time of flight mass spectroscopy in the diagnosis of patients with mycotic diseases. *Expert review of molecular diagnostics*. 2019;19(3):241-248. doi:10.1080/14737159.2019.1574572
18. Patterson TF, Thompson GR, 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326 [doi]
19. Eigl S, Hoenigl M, Spiess B, et al. Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. *Medical mycology*. 2017;55(5):528-534. doi:10.1093/mmy/myw102 [doi]
20. Mercier T, Guldentops E, Lagrou K, Maertens J. Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age. *Frontiers in microbiology*. 2018;9:661. doi:10.3389/fmicb.2018.00661 [doi]
21. Bergeron A, Porcher R, Sulahian A, et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. *Blood*. 2012;119(8):1831-7; quiz 1956. doi:10.1182/blood-2011-04-351601 [doi]
22. Miceli MH, Graziutti ML, Woods G, et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. *Clin Infect Dis*. May 1 2008;46(9):1412-22. doi:10.1086/528714
23. Nouér SA, Nucci M, Kumar NS, Graziutti M, Barlogie B, Anaissie E. Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. *Clin Infect Dis*. Oct 2011;53(7):671-6. doi:10.1093/cid/cir441
24. Huygens S, Dunbar A, Buil JB, et al. Clinical Impact of Polymerase Chain Reaction-Based Aspergillus and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study. *Clin Infect Dis*. Jul 5 2023;77(1):38-45. doi:10.1093/cid/ciad141
25. Smith DJ, Gold JAW, Chiller T, et al. Update on Outbreak of Fungal Meningitis among U.S. Residents who Received Epidural Anesthesia at Two Clinics in Matamoros, Mexico. *Clin Infect Dis*. Sep 22 2023;doi:10.1093/cid/ciad570
26. Miglioretti DL, Johnson E, Williams A, et al. The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. *JAMA Pediatr*. Aug 1 2013;167(8):700-7. doi:10.1001/jamapediatrics.2013.311
27. Greenwood TJ, Lopez-Costa RI, Rhoades PD, et al. CT Dose Optimization in Pediatric Radiology: A Multiyear Effort to Preserve the Benefits of Imaging While Reducing the Risks. *Radiographics*. Sep-Oct 2015;35(5):1539-54. doi:10.1148/rg.2015140267
28. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 1997;15(1):139-147.
29. Vehreschild JJ, Heussel CP, Groll AH, et al. Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis. *Eur Radiol*. Aug 2017;27(8):3275-3282. doi:10.1007/s00330-016-4717-4
30. Egge SL, Wurster S, Cho SY, et al. Co-Occurrence of Gram-Negative Rods in Patients with Hematologic Malignancy and Sinopulmonary Mucormycosis. *J Fungi (Basel)*. Jan 4 2024;10(1)doi:10.3390/jof10010041
31. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. *Cancer*. May 15 2008;112(10):2309-12. doi:10.1002/cncr.23441

32. Thompson GR, 3rd, Jenks JD, Baddley JW, et al. Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management. *Clin Microbiol Rev.* Sep 21 2023;36(3):e0001923. doi:10.1128/cmr.00019-23
33. Gamaletsou MN, Rammaert B, Brause B, et al. Osteoarticular Mycoses. *Clin Microbiol Rev.* Dec 21 2022;35(4):e0008619. doi:10.1128/cmr.00086-19
34. Schwartz S, Reisman A, Troke PF. The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. *Infection.* 2011;39(3):201-210. doi:10.1007/s15010-011-0108-6
35. Agarwal R, Singh Sehgal I, Muthu V, et al. Revised clinical practice guidelines for diagnosing, classifying, and treating allergic bronchopulmonary aspergillosis/mycoses: a Delphi statement from the ISHAM-ABPA working group. *Eur Respir J.* Mar 7 2024;doi:10.1183/13993003.00061-2024
36. Lv Q, Elders B, Warris A, Caudri D, Ciet P, Tiddens H. Aspergillus-related lung disease in people with cystic fibrosis: can imaging help us to diagnose disease? *Eur Respir Rev.* Dec 31 2021;30(162)doi:10.1183/16000617.0103-2021
37. Van Braeckel E, Page I, Davidsen JR, et al. Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. *Eur Respir J.* Jun 2022;59(6)doi:10.1183/13993003.02950-2021
38. Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. *The Lancet Infectious diseases.* 2016;16(7):828-837. doi:S1473-3099(16)00071-2 [pii]
39. Özbek L, Topçu U, Manay M, et al. COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases. *Clin Microbiol Infect.* Mar 13 2023;doi:10.1016/j.cmi.2023.03.008
40. Millon L, Caillot D, Berceanu A, et al. Evaluation of Serum Mucorales Polymerase Chain Reaction (PCR) for the Diagnosis of Mucormycoses: The MODIMUCOR Prospective Trial. *Clin Infect Dis.* Sep 14 2022;75(5):777-785. doi:10.1093/cid/ciab1066
41. Rocchi S, Scherer E, Mengoli C, et al. Interlaboratory evaluation of Mucorales PCR assays for testing serum specimens: A study by the fungal PCR Initiative and the Modimucor study group. *Medical Mycology.* 2020;doi:10.1093/mmy/myaa036
42. Aerts RB, K.; Lagrou, K.; Maertens, J. Mucorales PCR to track down Aspergillus and Mucorales coinfections in at-risk hematology patients: a case-control study. presented at: Mycology; 2022; London.
43. Guegan H, Iriart X, Bougnoux ME, Berry A, Robert-Gangneux F, Gangneux JP. Evaluation of MucorGenius® mucorales PCR assay for the diagnosis of pulmonary mucormycosis. *J Infect.* Aug 2020;81(2):311-317. doi:10.1016/j.jinf.2020.05.051
44. Roilides E, Zaoutis TE, Walsh TJ. Invasive zygomycosis in neonates and children. *Clin Microbiol Infect.* Oct 2009;15 Suppl 5:50-4. doi:10.1111/j.1469-0691.2009.02981.x
45. Nucci M, Marr KA, Vehreschild MJ, et al. Improvement in the outcome of invasive fusariosis in the last decade. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.* 2013;doi:10.1111/1469-0691.12409 [doi]
46. Litvintseva AP, Lindsley MD, Gade L, et al. Utility of (1-3)-beta-D-glucan testing for diagnostics and monitoring response to treatment during the multistate outbreak of fungal meningitis and other infections. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2014;58(5):622-630. doi:10.1093/cid/cit808 [doi]
47. Smith RM, Schaefer MK, Kainer MA, et al. Fungal infections associated with contaminated methylprednisolone injections. *N Engl J Med.* Oct 24 2013;369(17):1598-609. doi:10.1056/NEJMoa1213978
48. Friedman DZP, Theel ES, Walker RC, Vikram HR, Razonable RR, Vergidis P. Serial Bronchoalveolar Lavage Fluid Aspergillus Galactomannan and Treatment Response in Invasive Pulmonary Aspergillosis. *Open Forum Infectious Diseases.* 2024;doi:10.1093/ofid/ofae114

49. Goshia T, Aralar A, Wiederhold N, et al. Universal digital high-resolution melting for the detection of pulmonary mold infections. *J Clin Microbiol*. Jun 12 2024;62(6):e0147623. doi:10.1128/jcm.01476-23
50. Hoenigl M, Egger M, Price J, Krause R, Prattes J, White PL. Metagenomic Next-Generation Sequencing of Plasma for Diagnosis of COVID-19-Associated Pulmonary Aspergillosis. *J Clin Microbiol*. Feb 21 2023:e0185922. doi:10.1128/jcm.01859-22
51. Sehgal IS, Arora K, Cornely OA, et al. Characterization of Treatment Response Outcomes in Chronic Pulmonary Aspergillosis: CPAnet Definitions Versus the Existing Criteria. *Mycopathologia*. Oct 2023;188(5):721-730. doi:10.1007/s11046-023-00751-z
52. Douglas AP, Thursky KA, Worth LJ, et al. FDG PET/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging. *Eur J Nucl Med Mol Imaging*. Jan 2019;46(1):166-173. doi:10.1007/s00259-018-4062-8
53. Thornton CR. Molecular Imaging of Invasive Pulmonary Aspergillosis Using ImmunoPET/MRI: The Future Looks Bright. Review. *Frontiers in Microbiology*. 2018-April-09 2018;9(691)doi:10.3389/fmicb.2018.00691